Search results
Results from the WOW.Com Content Network
Favored distribution of vaccines within one or a few select countries, called "vaccine sovereignty", is a criticism of some of the vaccine development partnerships, [39] [42] such as for the AstraZeneca-University of Oxford vaccine candidate, concerning whether there may be [needs update] prioritized distribution first within the UK and to the ...
Moderna was founded in 2010 by Derrick Rossi, Timothy A. Springer, Kenneth R. Chien, Robert S. Langer, and Noubar Afeyan. [9] Stéphane Bancel, the current CEO, was appointed as CEO in 2011. [6] [10] Between 2011 and 2017, Moderna raised $2 billion in venture capital funding. [7] [8]
The Moderna news followed preliminary results from the Pfizer-BioNTech vaccine candidate, BNT162b2, with Moderna demonstrating similar efficacy, but requiring storage at the temperature of a standard medical refrigerator of 2–8 °C (36–46 °F) for up to thirty days or −20 °C (−4 °F) for up to four months, whereas the Pfizer-BioNTech ...
National regulatory authorities have granted full or emergency use authorizations for 40 COVID-19 vaccines.. Ten vaccines have been approved for emergency or full use by at least one stringent regulatory authority recognized by the World Health Organization (WHO): Pfizer–BioNTech, Oxford–AstraZeneca, Sinopharm BIBP, Moderna, Janssen, CoronaVac, Covaxin, Novavax, Convidecia, and Sanofi ...
1 dose of new Pfizer, Moderna, or Novavax vaccine. First-time vaccine recipients who opt for Novavax need 2 doses. Children 5 to 11. 1 dose of new Pfizer or Moderna vaccine. Children 6 months to 4 ...
Moderna Novavax: Days 0 and 56–84 Phase II (1,050) [333] Mar 2021 – Sep 2022, United Kingdom: Convidecia: ZF2001: Days 0 and 28 Days 0 and 56 Phase IV (120) [337] Apr–Dec 2021, China: Oxford–AstraZeneca Pfizer–BioNTech Days 0 and 28 Phase II (676) [338] Apr 2021 – Apr 2022, Spain: Oxford–AstraZeneca Pfizer–BioNTech Moderna ...
South Africa's Afrigen Biologics has used the publicly available sequence of Moderna Inc's mRNA COVID-19 vaccine to make its own version of the shot, which could be tested in humans before the end ...
LONDON (Reuters) -Pfizer and Moderna's legal battle over their rival COVID-19 vaccines looks set to continue after London's High Court gave a mixed ruling on two of Moderna's patents, likely ...